title: IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C.
abstract: Single-nucleotide polymorphisms (SNPs) in the Interleukin-28B (IL28B) gene and rs4273729 in the human leukocyte antigen (HLA) gene in chronic hepatitis C (CHC) virus infection are important for predicting treatment outcome. In this study, the distribution of IL28B SNPs (rs12979860 and rs12980275) and HLA rs4273729 in rapid virologic response (RVR), complete early virologic response (cEVR) and sustained virologic response (SVR) in HCV Iranian patients with CHC virus infection was assessed. IL28B genotyping and rs4273729 were performed using the amplification refractory mutation system (ARMS)-PCR and direct sequencing in 190 CHC virus infections, respectively. RVR, cEVR, and SVR were 53.2 %, 78.9 %, and 65.8 %, respectively. Multivariate regression analysis demonstrated that the responses significantly predicted SVR in patients with age <40 years (p = 0.008), HCV genotypes (p = 0.032), IL28B rs12979860 CC genotype (p < 0.001), rs12980275 AA genotype (p < 0.001), rs4273729 GG genotype (p < 0.001), RVR (p < 0.001) and cEVR (p = 0.024). Three critical predictor factors based on RVR response were rs12979860 CC genotype (p = 0.033), rs12980275 AA genotype (p < 0.001) and rs4273729 GG genotype (p < 0.001), while rs12980275 AA (p = 0.003) and rs4273729 GG genotypes (p < 0.001) predicted cEVR. For the first time in Iran, these results revealed that the rs12980275 and HLA rs4273729 are important for the treatment of CHC infection. These findings may help predict responses to CHC infection treatment and reduce the cost and side effects of therapy.
authors.affiliation: Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
authors.forename: Parvaneh
authors.initials: P
authors.lastname: Sedighimehr
authors.affiliation: Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
authors.forename: Shiva
authors.initials: S
authors.lastname: Irani
authors.affiliation: Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Sakhaee
authors.affiliation: Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.|Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Farzam
authors.initials: F
authors.lastname: Vaziri
authors.affiliation: Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Mohammadreza
authors.initials: M
authors.lastname: Aghasadeghi
authors.affiliation: Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Seyed Mehdi
authors.initials: SM
authors.lastname: Sadat
authors.affiliation: Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.|Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Fatemeh Rahimi
authors.initials: FR
authors.lastname: Jamnani
authors.affiliation: Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran. afateh2@gmail.com.|Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran. afateh2@gmail.com.
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Fateh
authors.affiliation: Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.|Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Seyed Davar
authors.initials: SD
authors.lastname: Siadat
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D060005:Genotyping Techniques; D006680:HLA Antigens / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D007492:Iran; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D000072230:Sustained Virologic Response; D013997:Time Factors; D055815:Young Adult; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D006680:HLA Antigens; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a